Skip to main content
SpringerLink
Log in

Diagnostic tests cost saving in suspected prostate cancer

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. prostate cancer

References

  1. Govers T, et al. Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer. 2019 Genitourinary Cancers Symposium : abstr. 91, 14 Feb 2019. Available from: URL: https://meetinglibrary.asco.org/record/170036/abstract

  2. Shore ND, et al. MiCheck performance: Comparator trial of MiCheck with PHI, % free PSA and PSA-The impact on decision making for prostate biopsy. 2019 Genitourinary Cancers Symposium : abstr. 199, 14 Feb 2019. Available from: URL: https://meetinglibrary.asco.org/record/169876/abstract

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diagnostic tests cost saving in suspected prostate cancer. PharmacoEcon Outcomes News 824, 10 (2019). https://doi.org/10.1007/s40274-019-5738-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5738-4

Search

Navigation